Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Advanced fibrosis/cirrhosis is associated with reduced likelihood of SVR, including to DAA therapy
  • IL28B genotype is associated with interferon responsiveness and SVR to interferon-based therapy[Ge 2009; Tanaka 2009; Thomas 2009]
    • Patients with favorable CC genotype have high rates of SVR to peginterferon/ribavirin dual therapy; incremental benefit with PI-based therapy, although many such patients will qualify for shortened PI therapy[Jacobson 2011b; Poordad 2012]

Action required